Table 2.
Patients with BMs (n = 82) |
Patient without BMs (n = 442) |
|||
---|---|---|---|---|
T-DXd (n = 43) | T-DM1 (n = 39) | T-DXd (n = 218) | T-DM1 (n = 224) | |
Median PFS (95% CI), months | 15.0 (12.5-22.2) | 3.0 (2.8-5.8) | NR (22.4-NE) | 7.1 (5.6-9.7) |
HR 0.25 (95% CI 0.13-0.45) | HR 0.30 (95% CI 0.22-0.40) | |||
12-month PFS rate (95% CI), % | 72.0 (55.0-83.5) | 20.9 (8.7-36.6) | 76.5 (70.0-81.8) | 36.4 (29.4-43.4) |
Median PFS, patients without prior BM therapy (95% CI), months | 16.8 (12.4-NE) (n = 20) |
5.6 (2.8-5.8) (n = 19) |
— | — |
HR 0.16 (95% CI 0.06-0.44) | — | — | ||
Median PFS, patients with prior BM therapy (95% CI), months | 14.1 (8.5-18.5) (n = 23) |
2.8 (2.6-NE) (n = 20) |
— | — |
HR 0.35 (95% CI 0.15-0.79) | — | — |
BMs, brain metastases; CI, confidence interval; HR, hazard ratio; NE, not estimable; NR, not reached; PFS, progression-free survival; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.